

**BBHIC**

**2018**

**BLOOM BURTON & CO.  
HEALTHCARE INVESTOR  
CONFERENCE  
2 May - 3 May, 2018**

A large, stylized white letter 'W' is centered on a solid orange background. The letter is composed of three vertical strokes, with the middle stroke being the tallest and the two side strokes being shorter and slightly curved at the top. The word 'WELCOME' is written in a bold, black, sans-serif font across the middle of the 'W'.

**WELCOME**

The Bloom Burton & Co. Healthcare Investor Conference hosts approximately 60 of Canada's premier publicly-traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry. The event attracts Canadian, U.S. and International investors who are interested in the latest developments in Canadian healthcare companies.

# From the Founders

---

**B**loom Burton & Co. exists to accelerate returns in the healthcare sector for both companies and investors. There is no greater illustration of the power of our platform than this conference, which has grown into Canada's flagship healthcare investment and networking event over the past seven years.

Bloom Burton and its affiliates continue to expand a talented and dedicated team to provide important services to accelerate the growth of companies and returns for investors. We offer investment banking services such as capital raising, M&A advisory, equity research, sales, trading and monetization planning, our scientific/business advisory work. We have expanded our direct investment capabilities by offering equity and debt funds to interested investors. Finally, entirely new companies we have founded and launched, such as Triumvira Immunologics, Appili Therapeutics, Grey Wolf Animal Health and our newly-minted Satellos Bioscience, will present at this very conference.

Last year's inaugural black-tie Bloom Burton Award Gala cemented itself as the preeminent award to celebrate each year's most important contributor in the Canadian healthcare sector. We hope to see you all at the 2018 Bloom Burton Award Gala on September 27, 2018, and our three finalists will be announced this week!

We are humbled to serve as the central catalyst for our industry and so proud of our team, who work tirelessly to serve our clients. We strive to produce exceptional deliverables and outcomes and we are here for you as you make new connections and plan for the success of the healthcare sector in Canada.

Have a wonderful conference!

Brian and Jolyon and the entire team

WiFi Access: SHERATON\_MEETINGS  
Access Code: BBHIC2018

 @bloomburton #BBHIC2018

 Bloom Burton & Co.



# CONTENTS

Agenda	<b>8</b>
Company Profiles	<b>12</b>
Keynote Speakers	<b>46</b>
Panelists	<b>50</b>
Bloom Burton & Co.	<b>58</b>
Logistics	<b>70</b>

A large, white, stylized outline of the letter 'A' is centered on a solid orange background. The letter is composed of two main parts: a tall, narrow upper section and a wider, shorter lower section. The word 'AGENDA' is printed in a bold, black, sans-serif font across the upper section of the 'A'.

**AGENDA**

# 2<sup>nd</sup> - 3<sup>rd</sup> May

**8:30** Conference Registration  
- Keynote Address

**9:30** Company Presentations

**12:00** Lunch & Panel Discussion

**1:30** Company Presentations

**4:30** End of presentations

**5:00** Networking

# 2<sup>nd</sup> May

## Wednesday

8:30 Conference Registration  
Keynote Address by John Carroll - Endpoints News  
TSX Market Opening Ceremony

### HALL A

### HALL B

### HALL C

9:30	Knight Therapeutics	Xenon Pharmaceuticals	Intellijoint Surgical
10:00	Cipher Pharmaceuticals	Essa Pharma	Perimeter Medical Imaging
10:30	Medicure	Zymeworks	Exact Imaging
11:00	Pediapharm	Medicenna Therapeutics	Think Research
11:30	Cardiome Pharma	Repare Therapeutics	Newtopia

12:00 Lunch  
Investor Panel “Investing in R&D Stage Healthcare Companies”  
Moderated by Brian Bloom



Paulina Hill - Polaris Partners  
Ting Jia - Hillhouse Capital  
Daniel Krizek - Surveyor Capital  
Stacey Seltzer - Aisling Capital  
Caroline Stout - EcoR1 Capital

1:30	HLS Therapeutics	Aptose Biosciences	Opsens
2:00	CRH Medical	Appili Therapeutics	Profound Medical
2:30	BioSyent Pharma	Resverlogix	Synaptive Medical
3:00	Nuvo Pharmaceuticals	Antibe Therapeutics	Conavi Medical
3:30	Crescita Therapeutics	Aequus Pharmaceuticals	Kardium
4:00	Searchlight Pharma	Eupraxia Pharmaceuticals	Klox Technologies

5:00 Cocktail reception hosted by Bloom Burton & Co. at the Sheraton Centre Hotel

# 3<sup>rd</sup> May Thursday

8:30 Conference Registration  
Keynote Address by Rajeev Shah - RA Capital Management

	HALL A	HALL B	HALL C
9:30	Revera	Bellus Health	Titan Medical
10:00	Interface Biologics	Theratechnologies	Dot Health
10:30	Greenbrook TMS	Aquinox Pharmaceuticals	Kneat Solutions
11:00	Hamilton Thorne	Trillium Therapeutics	Mavencare
11:30	Akumin	Fusion Pharmaceuticals	LED Medical Diagnostics

12:00 Lunch  
Investor Panel “Investing in Commercial Stage Healthcare Companies”  
Moderated by Brian Bloom



Ruoxi Chen - Warburg Pincus  
Jeffrey Schwartz - Bain Capital Life Sciences  
Thecla Sweeney - Birch Hill Equity Partners  
Tadd Wessel - Petrichor Healthcare Capital Management  
Jason Wild - JW Asset Management

1:30	STEMCELL Technologies	Aurinia Pharmaceuticals	7D Surgical
2:00	CannTrust	Clementia Pharmaceuticals	CellAegis Devices
2:30	Grey Wolf Animal Health	Immunovaccine	Avivagen
3:00	NeuPath Health	Triumvira Immunologics	IntelGenx
3:30	Acerus Pharmaceuticals	Turnstone Biologics	Microbix Biosystems
4:00	Precision NanoSystems	Parvus Therapeutics	Satellos Bioscience

5:00 Thank you for attending BBHIC2018!

A large, white, serif capital letter 'P' is centered on a solid orange background. The letter is hollow, and the words 'PRESENTING COMPANIES' are printed in a bold, black, sans-serif font across its middle. The text is centered horizontally within the width of the letter.

**PRESENTING COMPANIES**

## PRESENTING COMPANIES

---

**24**  
R&D

**16**  
Specialty  
Pharma

**12**  
Medical  
Technology

**6**  
Healthcare  
IT

**6**  
Healthcare  
Services

**2**  
Research  
Tools

## PRESENTING COMPANIES



### 7D Surgical

---

Thursday, May 3rd  
1:30pm; Hall C

---

7D Surgical is a privately-owned Toronto based company that develops advanced optical technologies and machine vision-based registration algorithms to improve surgical workflow and patient care. 7D Surgical's flagship FDA 510(k)-cleared and Health Canada approved MIGS™ system delivers profound improvement to surgical workflows in spine surgery, providing the promise of similar future advancements in other surgical specialties.

*Private*



### Acerus Pharma

---

Thursday, May 3rd  
3:30pm; Hall A

---

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men's and women's health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.

*TSX: ASP*



## **Aequus Pharmaceuticals** **Akumin**

---

**Wednesday, May 2nd**  
**3:30pm; Hall B**

---

Aequus Pharmaceuticals is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus' development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Our most recent addition to the development pipeline is a long-acting form of medical cannabis.

**TSX-V: AQS**

**Thursday, May 3rd**  
**11:30am; Hall A**

---

Akumin Inc. is a leading provider of outpatient diagnostic imaging services in the United States with 74 centers located in Florida, Pennsylvania, Delaware, Texas, Illinois and Kansas. Akumin's centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders, and therefore reducing unnecessary invasive procedures, minimizing the cost and improving outcomes for patients.

**TSX: AKU.U**

## PRESENTING COMPANIES



### Antibe Therapeutics

---

Wednesday, May 2nd  
3:00pm; Hall B

Antibe develops safer medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.

*TSX-V: ATE*



### Appili Therapeutics

---

Wednesday, May 2nd  
2:00pm; Hall B

Appili Therapeutics was founded to advance the global fight against infectious disease by matching clearly-defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors and society face in this space. Balancing near-to-market product candidates with higher-risk but potentially transformative early-stage programs, Appili's growing pipeline includes assets being developed by us as well as an active licensing program.

*Private*



## Aptose Biosciences

---

Wednesday, May 2nd  
1:30pm; Hall B

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

*TSX: APS      NASDAQ: APTO*



## Aquinox Pharmaceuticals

---

Thursday, May 3rd  
10:30am; Hall B

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Our lead drug candidate is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS). Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.

*NASDAQ: AQXP*

## PRESENTING COMPANIES



### **Aurinia Pharmaceuticals** **Avivagen**

---

**Thursday, May 3rd  
1:30pm; Hall B**

---

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of LN, FSGS, and DES. The company is headquartered in Victoria, BC and focuses its development efforts globally.

**TSX: AUP**      **NASDAQ: AUPH**

**Thursday, May 3rd  
2:30pm; Hall C**

---

Avivagen is a life sciences company that has developed a scientifically-proven product for replacing antibiotics in livestock feeds and to otherwise benefit human and animal health. Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) in Ottawa, Ontario and Charlottetown, Prince Edward Island.

**TSX-V: VIV**



## Bellus Health

---

Thursday, May 3rd  
9:30am; Hall B

---

BELLUS Health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. Its pipeline of projects includes the Company's lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs.

*TSX: BLU*



## BioSyent Pharma

---

Wednesday, May 2nd  
2:30pm; Hall A

---

BioSyent is a profitable growth oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are proven safe and effective, and have track records of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital, and international business units.

*TSX-V: RX*

## PRESENTING COMPANIES



### CannTrust

---

Thursday, May 3rd  
2:00pm; Hall A

As a federally regulated licensed producer, CannTrust™ brings more than 40 years of pharmacy and healthcare experience to the medical cannabis industry. We operate a 50,000 ft<sup>2</sup> hydroponic facility in Vaughan, Ontario, as well as the recently completed Phase 1 redevelopment of our 430,000 ft<sup>2</sup> Niagara Greenhouse Facility. Our healthcare team places patient access as a top priority and ensures that our customers have the support they need when purchasing medical cannabis.

*TSX: TRST*



### Cardiome Pharma

---

Wednesday, May 2nd  
11:30am; Hall A

Cardiome Pharma is a specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. Cardiome develops, acquires and commercializes brands for the in-hospital, acute care market segment. Our pipeline of products includes Trevyent®, a drug device combination designed to deliver Remodulin®, the world's leading treatment for pulmonary arterial hypertension.

*TSX: COM      NASDAQ: CRME*



## CellAegis Devices

---

Thursday, May 3rd  
2:00pm; Hall C

CellAegis Devices is a Toronto-based designer and manufacturer of safe, non-invasive and cost effective, cardio protective medical devices. CellAegis Devices has patented and developed the non-invasive autoRIC Device, which delivers Remote Ischemic Conditioning (RIC) therapy to patients with acute and chronic cardiovascular conditions. The autoRIC Device has CE Mark and Health Canada approvals for treatment during heart attacks, cardiothoracic or surgical procedures.

*Private*



## Cipher Pharmaceuticals

---

Wednesday, May 2nd  
10:00am; Hall A

Cipher is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America.

*TSX: CPH*

## PRESENTING COMPANIES



### **Clementia Pharmaceuticals**

---

**Thursday, May 3rd**  
**2:00pm; Hall B**

Clementia is a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company's lead candidate, palovarotene, a novel RAR $\gamma$  agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP), with additional clinical studies planned in multiple osteochondromas (MO, also known as hereditary multiple exostoses) and other diseases.

*NASDAQ: CMTA*

### **Conavi Medical**

---

**Wednesday, May 2nd**  
**3:00pm; Hall C**

Conavi Medical develops, manufactures, sells and supports technologies to help guide minimally invasive procedures. Our company commercializes technologies initially invented at Sunnybrook Research Institute in Toronto. Conavi's focus is on providing innovative image guidance technologies for minimally invasive procedures, with an initial emphasis on cardiovascular procedures.

*Private*



## NeuPath Health

---

Thursday, May 3rd  
3:00pm; Hall A

---

NeuPath Health specializes in the management and treatment of chronic pain. With 12 clinics across Ontario operating under two banners, NeuPath Health is the largest provider of chronic pain management services in Canada.

*Private*



## Crescita Therapeutics

---

Wednesday, May 2nd  
3:30pm; Hall A

---

Crescita is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin.

*TSX: CTX*

## PRESENTING COMPANIES



### CRH Medical

---

Wednesday, May 2nd  
2:00pm; Hall A

CRH Medical is a North American company focused on providing gastroenterologists throughout the U.S. with innovative services and products for the treatment of gastrointestinal diseases. The CRH O'Regan System is a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. CRH distributes the O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package.

*TSX: CRH      NYSE American: CRHM      Private*



### Dot Health

---

Thursday, May 3rd  
10:00am; Hall C

Dot Health synchronizes, stores, and updates in real-time all of your health information. A mobile and web search interface helps query this database using simple, natural language that can be used by you/a paramedic/any healthcare professional to locate and serve the most important information about your health at any given point in time.



## ESSA Pharma

---

Wednesday, May 2nd  
10:00am; Hall B

---

ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer (“CRPC”) in patients whose disease is progressing despite treatment with current therapies. ESSA believes that its proprietary compounds can significantly expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies.

*TSX-V: EPI      NASDAQ: EPIX*

## Eupraxia Pharmaceuticals

---

Wednesday, May 2nd  
4:00pm; Hall B

---

Eupraxia Pharmaceuticals operates as a drug delivery technology company. It specializes in taking existing drugs and making them targeted and effective. The company’s disruptive technology in injectable drug delivery enhances existing drug efficacy, patient compliance, and safety in therapies for prevalent diseases affecting patients across the globe.

*Private*

## PRESENTING COMPANIES



### Exact Imaging

---

Wednesday, May 2nd  
10:30am; Hall C

---

Exact Imaging is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. Exact Imaging's ExactVu™ has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada).

*Private*



### Fusion Pharmaceuticals

---

Thursday, May 3rd  
11:30am; Hall B

---

Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. Its lead program, FPX-01 has a clinical trial planned for 2018. Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing, and forming new strategic partnerships.

*Private*



## Greenbrook TMS

---

Thursday, May 3rd  
10:30am; Hall A

---

Greenbrook TMS NeuroHealth Centers specializes in Transcranial Magnetic Stimulation Therapy for depression. We are North America's largest provider of TMS Therapy. TMS is an FDA-cleared, non-drug, non-sedating, non-invasive medical treatment for patients suffering with depression without any of the typical side effects experienced with antidepressant medications. TMS can be used as a stand-alone treatment or in conjunction with medication.

*Private*

## Grey Wolf Animal Health

---

Thursday, May 3rd  
2:30pm; Hall A

---

Grey Wolf Animal Health is an emerging animal health specialty pharmaceutical startup. Grey Wolf's vision is to establish and grow itself as a fully integrated Canadian animal health company. The company plans to gain market share through careful selection of products that meet the needs of Canadian veterinarians and pet owners. Grey Wolf is on track to commercialize a portfolio of more than 25 products in five years with revenues of more than \$15M+.

*Private*

# PRESENTING COMPANIES



HLS Therapeutics Inc.

## Hamilton Thorne

---

Thursday, May 3rd  
11:00am; Hall A

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Our customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotech companies, and other commercial research establishments.

*TSX-V: HTL*

## HLS Therapeutics

---

Wednesday, May 2nd  
1:30pm; Hall A

HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established, branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas.

*TSX-V: HLS*



## Immunovaccine

---

Thursday, May 3rd  
2:30pm; Hall B

Immunovaccine is a clinical-stage biopharmaceutical corporation dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Corporation's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.

*TSX: IMV*



## IntelGenx

---

Thursday, May 3rd  
3:00pm; Hall C

IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Our state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients.

*TSX-V: IGX      NASDAQ: IGXT*

## PRESENTING COMPANIES



### Intellijoint Surgical

---

Wednesday, May 2nd  
9:30am; Hall C

Intellijoint Surgical® develops and commercializes surgical navigation solutions. Intellijoint's flagship product, intellijoint HIP® provides surgeons with real-time, intraoperative measurements to ensure proper positioning of orthopaedic implants during Total Hip Arthroplasty. Intellijoint is committed to driving clinical results through the development of solutions that are accessible, fast, and easy-to-use. Intellijoint is setting the new standard in miniature 3D surgical navigation.

*Private*



### Interface Biologics

---

Thursday, May 3rd  
10:00am; Hall A

Interface Biologics (IBI) is an early commercial stage privately held company developing innovative material science technologies for products that save lives and improve patient outcomes. IBI's primary technology focus areas are anti-thrombogenic additives that reduce thrombosis in blood contacting medical devices and polymer enabled drug delivery platforms.

*Private*



## Kardium

---

Wednesday, May 2nd  
3:30pm; Hall C

---

Kardium is a technology pioneer working to advance medical device technology in the diagnosis and treatment of atrial fibrillation. Kardium was founded in 2007 and has built an outstanding team with a track record of excellence in medicine, business, and engineering. We have been working to develop the Globe mapping and ablation system which provides a complete system to assist in the diagnosis and treatment of atrial fibrillation.

*Private*



## Klox Technologies

---

Wednesday, May 2nd  
4:00pm; Hall C

---

Klox is a company focused on developing and commercializing products based on its proprietary Fluorescence Biomodulation technology platform, previously known as BioPhotonics, to address skin and soft tissue disorders. Klox is advancing its programs as part of its multiple franchises focusing on indications across Dermatology, Wound Care, and Oral Health.

*Private*

## PRESENTING COMPANIES



### **Kneat Solutions**

---

**Thursday, May 3rd  
10:30am; Hall C**

---

Kneat, develops and markets the next generation Kneat Gx software platform. Multiple business processes can be configured on the platform from equipment to computer system validation, through to production record execution and quality document management. Kneat Gx allows users to author, review, approve, execute testing online, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform.

*Private*



### **Knight Therapeutics**

---

**Wednesday, May 2nd  
9:30am; Hall A**

---

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD.

*TSX: GUD*



## LED Medical Diagnostics Mavencare

---

Thursday, May 3rd  
11:30am; Hall C

---

LED Medical is a dental imaging technology provider focused on delivering state-of-the-art imaging software and systems. Through its wholly-owned subsidiaries, LED Medical has provided dentists and oral health specialists with advanced diagnostic imaging products and software for over 20 years. Our proprietary technologies include the VELscope Vx Enhanced Oral Assessment, TUXEDO Intraoral Sensors, Apteryx's XrayVision, XVWeb and XrayVision DCV imaging software solutions.

*TSX-V: LMD*

Thursday, May 3rd  
11:00am; Hall C

---

Mavencare is the most clinically advanced home health company that leverages technology to enable seniors to safely age at home. Mavencare's vision is to revolutionize home health care and create a world where people can live out their lives in the comfort of their own homes.

*Private*

## PRESENTING COMPANIES



### **Medicenna Therapeutics** **Medicure**

---

**Wednesday, May 2nd**  
**11:00am; Hall B**

---

Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs). Its wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the IL4R, which is over-expressed by at least 20 different types of cancer. Medicenna's lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical trial for rGBM at leading brain cancer centres in the US.

**TSX: MDNA**

**Wednesday, May 2nd**  
**10:30am; Hall A**

---

Medicure is a pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. cardiovascular market. The primary focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and the launch of ZYPITAMAG™ (pitavastatin magnesium) in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc.

**TSX-V: MPH**



## Microbix Biosystems

---

Thursday, May 3rd  
3:30pm; Hall C

Microbix specializes in developing proprietary biological and technology solutions for human health and well-being. It manufactures a wide range of critical biological materials for the global diagnostics industry, notably antigens used in immunoassays or quality assessment products. Microbix' products are sold to more than 100 customers worldwide, primarily to multinational diagnostics companies and laboratory accreditation organizations.

*TSX: MBX*



## Newtopia

---

Thursday, May 3rd  
9:30am; Hall C

Newtopia is a precision health company leveraging genetic testing and the latest engagement science to inspire individuals to live healthier every day and reduce their risk of developing preventable chronic diseases. Newtopia is partnering with insurers, employers and brands to offer disease prevention and management programs to risk-assessed individuals that deliver proven sustainable outcomes, quantifiable cost savings and a substantive ROI.

*Private*

## PRESENTING COMPANIES



### **Nuvo Pharmaceuticals**

---

Wednesday, May 2nd  
3:00pm; Hall A

---

Nuvo is a global commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities. Nuvo has four commercial products that are available in a number of countries; Pennsaid® 2%, Pennsaid, Resultz and the heated lidocaine/tetracaine patch. Nuvo manufactures Pennsaid for the global market, Pennsaid 2% for the U.S. market and the bulk drug product for the HLT Patch at its FDA, Health Canada and E.U. approved manufacturing facility in Varennes, Québec.

*TSX: NRI*



### **Opsens**

---

Wednesday, May 2nd  
1:30pm; Hall C

---

Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.

*TSX: OPS*



## Parvus Therapeutics

---

Thursday, May 3rd  
4:00pm; Hall B

---

Parvus Therapeutics is a privately-held biopharmaceutical company engaged in the development and commercialization of Navacim therapeutics, novel nanoparticle based immune complexes that induce the in vivo expansion of specific regulatory cells resulting in the restoration of immune homeostasis. Navacims can be readily tailored to target a broad range of autoimmune diseases and have the potential to radically improve the lives of patients suffering from these diseases.

*Private*



## Pediapharm

---

Wednesday, May 2nd  
11:00am; Hall A

---

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world.

*TSX-V: PDP*

# PRESENTING COMPANIES



## Perimeter Medical Imaging

---

Wednesday, May 2nd  
10:00am; Hall C

---

Perimeter Medical Imaging develops, patents, and commercializes advanced intra-operative imaging tools that allow surgeons, radiologists and pathologist to better assess microscopic tissue structures during the surgical procedure. Perimeter's OTIS™ is the only solution that provides rapid, automated, micron resolution visualization of the entire surface of the excised tissue specimen, while reliably representing orientation for improved in-surgery decisions.

*Private*



## Precision NanoSystems

---

Thursday, May 3rd  
11:00am; Hall A

---

Precision NanoSystems creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI's proprietary NanoAssemblr Platform enables the rapid, reproducible and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body.

*Private*



## Profound Medical

---

Wednesday, May 2nd  
2:00pm; Hall C

---

The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patients and clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases.

*TSX-V: PRN*



## Repair Therapeutics

---

Wednesday, May 2nd  
11:30am; Hall B

---

Repair is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repair's platform combines a proprietary, high-throughput, CRISPR-enabled gene editing target discovery method with high-resolution protein crystallography, computational biology and clinical informatics.

*Private*

# PRESENTING COMPANIES



## Resverlogix

---

Wednesday, May 2nd  
2:30pm; Hall B

Resverlogix is a late-stage clinical biotechnology company dedicated to improving and saving the lives of patients with high-risk cardiovascular disease, diabetes mellitus, and chronic kidney disease. We are developing an advanced epigenetic drug called apabetalone for the treatment of high-risk cardiovascular disease patients who also have type 2 diabetes mellitus and low high-density lipoprotein.

*TSX: RVX*



## Revera

---

Thursday, May 3rd  
9:30am; Hall A

Revera is a leading owner, operator and investor in the senior living sector committed to helping older adults live life to the fullest. Through its portfolio of partnerships, Revera owns or operates more than 500 properties across Canada, the United States and the United Kingdom, offering seniors' apartments, independent living, assisted living, memory care and long term care. Revera's vision is to celebrate the ageless spirit of people.

*Private*



## Satellos Bioscience

---

Thursday, May 3rd  
4:00pm; Hall C

Satellos Bioscience is a biotechnology company harnessing intrinsic stem cell regeneration mechanisms for the pharmacological treatment of high need diseases. Our technology is based on a series of landmark discoveries by our scientific founder Dr. Michael Rudnicki. Pioneering a novel understanding of how to modulate the orientation by which stem cells divide and replenish, our first program addresses Duchenne Muscular Dystrophy (DMD), a severe genetic disease of children that currently leads to death in early adulthood.

*Private*

## Searchlight Pharma

---

Wednesday, May 2nd  
4:00pm; Hall A

Searchlight Pharma, headquartered in Montreal, aspires to become a leading Canadian-based specialty healthcare company through best-in class execution of the search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products that improve life-long human health and wellness. With a core focus on women's health, urology, and pediatrics, our team is committed to improving people's lives by bringing the right products to market.

*Private*

## PRESENTING COMPANIES



### STEMCELL Technologies

---

Thursday, May 3rd  
1:30pm; Hall A

STEMCELL Technologies Inc. is a Canadian biotechnology company that develops specialty cell culture media, cell isolation systems and accessory products for life science research. Driven by science and a passion for quality, STEMCELL supports the advancement of scientific research around the world with our catalogue of more than 2000 cell biology research tools.

*Private*

### Synaptive Medical

---

Wednesday, May 2nd  
2:30pm; Hall C

Synaptive Medical Inc., a Toronto-based medical device and technology company, collaborates with leading clinicians and healthcare systems to revolutionize products and services that cross traditional barriers to enable continuous improvement in care delivery in and beyond the operating room. Synaptive's integrated BrightMatter™ solutions are designed to give clinicians the right information they need to ensure the best possible outcomes for patients.

*Private*



## **Theratechnologies**

---

**Thursday, May 3rd  
10:00am; Hall B**

---

Theratechnologies is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients.

*TSX: TH*

## **Think Research**

---

**Wednesday, May 2nd  
11:00am; Hall C**

---

Think Research's mission is to organize the world's health knowledge so everyone gets the best care. The company takes the ever-growing body of clinical evidence and health care algorithms to create software applications that drive high quality clinical decision making. Think Research's solutions are provided through a secure, multi-application platform that is used by clinicians and patients at the point of care, and is deployed in over 1,000 facilities in Canada, the US and the EU.

*Private*

## PRESENTING COMPANIES



### Titan Medical

---

Wednesday, May 2nd  
11:30am; Hall C

---

Titan is focused on the design, development and commercialization of new robotic surgical technologies. The Company is advancing the development of a robust product portfolio with the objective to meet current needs in surgical procedures which would benefit all stakeholders, including patients, surgeons, and hospitals. The Company currently has under development the SPORT Surgical System, a single-port robotic surgical system.

*TSX: TMD*



### Trillium Therapeutics

---

Thursday, May 3rd  
11:00am; Hall B

---

Trillium Therapeutics is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, TTI-621, is a SIRP $\alpha$ Fc fusion protein that consists of the CD47-binding domain of human SIRP $\alpha$  linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal.

*TSX: TRIL      NASDAQ: TRIL*



## **Triumvira Immunologics**

---

**Thursday, May 3rd  
3:00pm; Hall B**

Triumvira Immunologics is a biotechnology company developing a novel platform for engineering T cells to attack cancers. Our innovative and proprietary technology for reprogramming T cells, called the T Cell-Antigen Coupler (or TAC), may possess advantages over other approaches to engineered T cells owing to the distinct biology of TAC-T cells. We have licensed the TAC technology from McMaster University and intend to begin human testing in 2018.

*Private*

## **Turnstone Biologics**

---

**Thursday, May 3rd  
3:30pm; Hall B**

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Our first-of-its-kind investigational oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual's own immune system to attack the tumor, with the goal of preventing recurrence and delivering a cure.

*Private*

## PRESENTING COMPANIES



XENON



### Xenon Pharmaceuticals

---

Wednesday, May 2nd  
9:30am; Hall B

Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy, migraine, and pain.

*NASDAQ: XENE*

### Zymeworks

---

Wednesday, May 2nd  
10:30am; Hall B

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Our suite of complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. Our lead product candidate, ZW25, is a novel bispecific antibody that is being evaluated in an adaptive Phase 1 clinical trial.

*TSX: ZYME*

*NASDAQ: ZYME*

## Public Companies

---

Acerus Pharmaceuticals  
Aequus Pharmaceuticals  
Akumin  
Antibe Therapeutics  
Aptose Biosciences  
Aquinox Pharmaceuticals  
Aurinia Pharmaceuticals  
Avivagen  
Bellus Health  
BioSyent Pharma  
CannTrust  
Cardiome Pharma  
Cipher Pharmaceuticals  
Clementia Pharmaceuticals  
Crescita Therapeutics  
CRH Medical  
ESSA Pharma  
Hamilton Thorne  
HLS Therapeutics  
Immunovaccine  
IntelGenx  
Knight Therapeutics  
LED Medical Diagnostics  
Medicenna Therapeutics  
Medicure  
Microbix Biosystems  
Nuvo Pharmaceuticals  
Opsens  
Pediapharm  
Profound Medical  
Resverlogix  
Theratechnologies  
Titan Medical  
Trillium Therapeutics  
Xenon Pharmaceuticals  
Zymeworks

## Private Companies

---


7D Surgical  
Appili Therapeutics  
CellAegis Devices  
Conavi Medical  
Dot Health  
Eupraxia Pharmaceuticals  
Exact Imaging  
Fusion Pharmaceuticals  
Greenbrook TMS  
Grey Wolf Animal Health  
Intellijoint Surgical  
Interface Biologics  
Kardium  
Klox Technologies  
Kneat Solutions  
Mavencare  
NeuPath Health  
Newtopia  
Parvus Therapeutics  
Permieter Medical Imaging  
Precision NanoSystems  
Repare Therapeutics  
Revera  
Satellos Bioscience  
Searchlight Pharma  
STEMCELL Technologies  
Synaptive Medical  
Think Research  
Triumvira Immunologics  
Turnstone Biologics

# John Carroll

---

Co-founder, Endpoints News

Endpoints News is an independent news organization,  
reporting and analyzing the top global biotech and  
pharmaceutical R&D news of the day.



## **John D. Carroll**

John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism.

A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from his daily industry coverage for FierceBiotech, where he was named editor in 2003, leaving in 2016, Carroll has been a regular speaker at biotech events around the globe. He's been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. He's also keynoted at biotech gatherings around the world and addressed student audiences at MIT

and Harvard. Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. He spent 6 years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times.

# Rajeev Shah

Managing Director and Portfolio Manager,  
RA Capital Management

RA Capital Management (“RA Capital”) is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics.



Rajeev Shah is a Managing Director and Portfolio Manager at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. He is also active in the firm's outreach efforts, speaking frequently both at industry events and in classrooms. Raj holds a BS from Cornell University, where he majored in Chemistry with a concentration in Economics. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. He is also an active member of the Big Brothers of Massachusetts Bay program.

# PANELISTS

Our panelists are recognized industry leaders who have made worthwhile contributions to the healthcare sector both within Canada and globally. This year, our panelists will discuss *Investing in R&D Stage Healthcare Companies* and *Investing in Commercial Stage Healthcare Companies*.

### Paulina Hill


---

Paulina Hill joined Polaris in 2012 and focuses on investments in healthcare from the Boston office. Paulina serves on the boards of Arsenal Medical, Faraday Pharmaceuticals, Kala Pharmaceuticals (NASDAQ:KALA), KinDex Pharmaceuticals, CAMP4 and Neuronetics. She is an observer on the boards of 480 Biomedical, Microchips Biotech and Sofregen.

In addition to her investing role, Paulina has served as founding CEO of Polaris-backed CAMP4, a biotech startup based in Cambridge, MA. She also serves on the board of The Capital Network, a non-profit that provides fundraising education to startup entrepreneurs. Prior to joining Polaris, Paulina completed her postdoctoral fellowship in the Chemical Engineering department at MIT in Bob Langer's lab. Paulina is the founding President of the MIT Postdoctoral Association and served on the MIT Intellectual Property Presidential Committee.

Paulina completed her PhD in Molecular Medicine with a Tissue Engineering focus at Wake Forest University School of Medicine. Paulina graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. ECU honored Paulina with the Incredible Women's award in 2017.

Paulina was born in Poland and grew up in Toronto. She attended East Carolina on an athletic scholarship, serving as Captain of the women's tennis team.



### Ting Jia

---

Mr. Ting Jia "TJ" serves as a Managing Director at Hillhouse Capital Management, where he is primarily responsible for managing the firm's investments in the life science sectors.

Prior to that, he worked as an analyst at BVF Partners LP and as a management consultant at McKinsey & Company. He received his Ph.D in Immunology from Memorial Sloan-Kettering Center and Weill Cornell, and a B.S. in Biological Sciences from Sun Yat-sen University.

### Daniel Krizek

---

Daniel Krizek is a Portfolio Manager at Surveyor Capital, where he focuses on investments across the biotechnology sector. Prior to joining Surveyor, Mr. Krizek served as Director at Bain Capital / Brookside Fund, where he managed investments in biotechnology, med-tech, and diagnostics. Beside public equities, Mr. Krizek also focuses on private investments in highly innovative biotech companies, ranging from venture capital stage to mezzanine / pre-IPO. Before Bain Capital, Mr. Krizek was a consultant at McKinsey, where he advised companies in pharmaceutical, biotech, and med-tech sectors. Mr. Krizek received a B.A. from Stanford, and holds CFA and CAIA designations.



### Stacey Seltzer

---

Ms. Seltzer joined Aisling in 2008 and currently serves as a Partner. Previously, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the U.S. Schering-Plough Brand Lead for Zetia. While in business development, Ms. Seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.

Ms. Seltzer serves as a director of Aimmune Therapeutics and Promentis Pharmaceuticals, and as a Board observer of AVROBIO and Prolacta Bioscience. Previously, she served as a director of Miramar Labs (acquired by Sientra), led Aisling's investment in Synergy Pharmaceuticals and PreCision Dermatology (acquired by Valeant), and was a Board observer for Agile Therapeutics, Durata Therapeutics (acquired by Actavis) and ZELTIQ Aesthetics (acquired by Allergan). She was also closely involved in Aisling's investments in Aclaris, Cytos, Dermira and PowerVision. Ms. Seltzer serves on the Life Science Council for Springboard Enterprises, the National Council for the Humane Society of the US, and the Investment Advisory Board of of the Blavatnik Fund for Innovation at Yale.

Ms. Seltzer received her M.B.A. from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar. She received her M.S. and B.S. from Yale University, awarded cum laude in Molecular Biophysics and Biochemistry.



## PANEL DISCUSSION: Investing in R&D Stage Healthcare Companies

### Caroline Stout

---



Caroline Stout specializes in operational and scientific analysis at EcoR1 Capital LLC. In her role as an EcoR1 Analyst, Ms. Stout informs the fund's investment decisions by assessing clinical data and corporate insights to gain broad insights into biotechnology companies, markets and emerging science. She previously worked as an Investment Banking Analyst at Credit Suisse in New York, performing due diligence and financial valuation analysis for healthcare companies. She has experience working on a range of transactions in the healthcare and biotechnology sectors, including multi-billion dollar leveraged buyouts, initial public offerings and follow-on equity raises. Ms. Stout graduated magna cum laude from Georgetown University with a Bachelor of Arts in Economics, a Pre-Medical concentration, and Cognitive Science minor.

## PANEL DISCUSSION: Investing in Commercial Stage Healthcare Companies

### Ruoxi Chen

---

Ruoxi Chen joined Warburg Pincus in 2011 based in New York, and focuses on investments in the healthcare sector. Prior to joining Warburg Pincus, Mr. Chen worked at the Carlyle Group in the U.S. Buyout Fund, and at Citigroup. Mr. Chen is a member of the Board of Directors of Singular Bio, Silk Road Medical, and Vertice Pharma. He received a B.S. magna cum laude in economics and computer science from Duke University and an M.B.A. from Harvard Business School.



## PANEL DISCUSSION: Investing in Commercial Stage Healthcare Companies

### Jeffrey Schwartz

---



Jeffrey Schwartz is a Managing Director of Bain Capital Life Sciences, where he is a founding member of the team. Prior to co-founding Bain Capital Life Sciences in 2016, he was a leader within the healthcare vertical of Bain Capital Private Equity. He currently is a board member of Hugel, QuVa Pharma and Springworks Therapeutics. Since joining Bain Capital, Mr. Schwartz has been actively involved in a wide spectrum of healthcare companies in which Bain Capital Private Equity has made investments including: Air Medical Group Holdings, Beacon Health Options, CRC Health, HCA, Lake Region Medical, Quintiles, and Warner Chilcott. In addition, he currently sits on the board of the Commonwealth School and the Boston Medical Center Philanthropic Trust. Prior to joining Bain Capital, Mr. Schwartz served as an Equity Research Analyst at Lehman Brothers, working in both New York and London. Mr. Schwartz received an MBA from the Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Yale University with a BA in economics.

### Thecla Sweeney

---

Thecla joined Birch Hill in 2004 when the group was still part of TD Capital. Thecla is Chair of the Boards of Directors of Mastermind Toys and Motion Specialties and she serves on the Board of Directors of Sleep Country Canada Holdings Inc. Thecla has served on the Boards of ACE Bakery, Atria Networks, Secunda Canada and TSC Stores.

Prior to joining Birch Hill, Thecla worked at Porter Airlines in Business Development, she was a consultant at Bain & Company and also spent three years in the Chairman's Office of George Weston Limited.

Outside of Birch Hill, Thecla serves on the Board as Co-Chair of the Canadian Women in Private Equity.

Thecla received her MBA from the Richard Ivey School of Business, Western University where she graduated as an Ivey Scholar and her BA (Honours) from Western University.



## PANEL DISCUSSION: Investing in Commercial Stage Healthcare Companies

### Tadd Wessel

---



Tadd S. Wessel is the founder and Managing Partner of Petrichor Healthcare Capital Management. Mr. Wessel was formerly a Managing Director at OrbiMed Advisors, where he led the build out of the healthcare special situations and structured finance business. Prior to OrbiMed, Mr. Wessel was a Vice President in the Drawbridge Special Opportunities Fund at Fortress Investment Group focused on healthcare investments. Mr. Wessel holds an A.B. from Princeton University.

### Jason Wild

---

Jason Wild is the President and Chief Investment Officer of JW Asset Management, LLC, the advisor for three investment partnerships. Mr. Wild received his license as a pharmacist in 1997, and subsequently founded JW Asset Management, LLC in 1998. The firm has a strong history of finding opportunities within the specialty pharmaceutical sector. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy where he received a bachelor's degree in Pharmacy.



**SPONSORS**

We gratefully acknowledge our sponsors who support our vision for the Canadian healthcare sector.

**Baker  
McKenzie.**

**b** | **Berkley**  
CANADA  
| a Berkley Company

*Blakes*

**BLG**  
Borden Ladner Gervais

**Deloitte.**

**EY**

**FASKEN**

*Johnson & Johnson* INNOVATION  
— JLABS —

 **JLT**

**LONGVIEW**  
COMMUNICATIONS & PUBLIC AFFAIRS

**mccarthy  
tetrault**

**NORTON ROSE FULBRIGHT**

**RICHARDSON GMP**

ROSEMARY HORWOOD WEALTH

**TMX** | Toronto Stock Exchange | TSX Venture Exchange | TSX Private Markets

**TORYS**  
LLP

**troutman  
sanders**

**W&R**  
Wilson Sonsini Goodrich & Rosati  
PROFESSIONAL CORPORATION

The Bloom Bu  
been dedicated  
the healthca  
industry fo  
decade. Our c  
and expe  
clients achiev  
to their mon

urton team has  
exclusively to  
are investment  
or more than a  
deep expertise  
rience lets our  
e a faster path  
etizing events.



bloom burton & co

/accelerating returns in healthcare

Our services help identify, cultivate and create investment opportunities in the healthcare sector on behalf of companies and investors.

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, healthcare IT, life science tools, animal health, nutrition and wellness.

Our seven business services work cohesively to accelerate monetization for both company and investor clients.

—  
Raising Capital & Financing

Sourcing capital to fund healthcare opportunities

—  
M&A Advisory

Enabling monetization through strategic transactions

—  
Equity Research

Influential opinions and insights on companies

—  
Sales & Trading

Generating returns for investors

—  
Monetization Planning

Helping realize the value of innovations

—  
Direct Investment

Maximizing opportunities in healthcare investing

—  
Company Creation

Establishing new opportunities in healthcare

We speak with large companies and investors every day, and we know what they are looking for. We are therefore the ideal group to help our companies plan their capital market strategies, investigate the relevance of new biological pathways, and consider new therapeutic indications and clinical designs, catalogue and diligence new products or companies for acquisition.

# SERVICES

## Raising Capital & Financing

From steering seed money to promising new life science ventures to facilitating private financing or raising public capital, Bloom Burton connects investors with attractive healthcare businesses poised for growth and profit. As investment bankers, we nurture relationships between worthy companies and engaged investors who want to provide funding and participate in the growth of the healthcare sector.

## M&A Advisory

The mergers and acquisitions advisory capability at Bloom Burton guides clients to conceptualize, structure and execute transactions to maximize returns and company performance. Our team's professional expertise in healthcare and intellectual property also allows us to guide our clients with scientific and technical due diligence on their M&A opportunities and development strategies.

## Equity Research

Our equity analysts ask the right questions, dig deeper for answers and find details others miss. Our research division covers key Canadian healthcare companies to understand how they operate, recognize their relative strengths and weaknesses, and determine the impact of clinical and commercial developments and competitive events.

### Sales & Trading

Using timely information, we are able to make markets and execute trades, generating returns for our investors and the companies we work with.

### Monetization Planning

Understanding the business opportunities to bring healthcare advances to market - and how to successfully utilize them - are key to any company's commercial and financial success. It is also key to investor returns.

Our management consulting practice provides capital market advice, plus scientific, clinical and medical insight to help innovative companies position themselves to profit from their good ideas and achieve a monetizing event. We structure our work as either defined projects or long-term arrangements.

### Direct Investment

We consult with and offer our extensive knowledge and experience in the healthcare industry to our affiliate Bloom Burton Investment Group and Stratigis Capital Advisors Inc., the managers of the following investment products which provide investors the opportunity to invest in a diversified portfolio of healthcare companies:

- 1) Bloom Burton Canadian Healthcare Fund
- 2) Bloom Burton Healthcare Structured Lending Fund I and II
- 3) Bloom Burton Healthcare Lending Trust I and II

### Company Creation

In very special situations, instead of providing services for cash fees, Bloom Burton partners with entrepreneurs and researchers to form and incubate new companies, in exchange for a founding equity position. Bloom Burton leverages all of its services and skills:

- Advise on the company's corporate and capital structure;
- Catalog and select the best target indications based on commercial, competitive and scientific considerations;
- Design the optimal international patent strategy;
- Design preclinical and clinical programs to produce valuable evidence for financing and partnering;
- Support the optimal regulatory strategy;
- Advise on the identification, license or acquisition of complimentary intellectual property and assets;
- Recruit the best management team and Board to help execute the Company's strategy;
- Create marketing materials to inform, engage and transact with investors and partners;
- Raise seed and subsequent private and public capital; and
- Leverage the entire Bloom Burton platform to increase the exposure of the Company.

At Bloom Burton & Co., we serve investors and companies seeking to make meaningful change to the healthcare industry. We identify the most impactful companies for our investor network and we provide tailor-made support solutions for management and Boards of healthcare companies.

The people who work at Bloom Burton have deep knowledge in medicine, science, patent and corporate law, finance and healthcare invention, development and commercialization.

As a result of our expertise and experience in healthcare, we have developed a disciplined methodology for helping companies grow faster.

Our methodology, and all of the services we offer, rest on six key pillars: deeper due diligence, a broader range of investment options, greater understanding of cross-border rules, relationships with international investors, engagement with the broader healthcare community, and a creative, tenacious, entrepreneurial culture.

We never blame “market conditions” or approach transactions as a “numbers game.”

Our long-term commitment to each investor and company challenges us to continuously refine our strategies until we achieve success. We are creative in our approach to financing and growth, and tenacious in finding the right transaction for all parties.

# OUR PEOPLE

## Executives



**Brian Bloom**  
Co-founder,  
Chairman & CEO



**Jolyon Burton**  
Co-founder, President  
& Head of Investment  
Banking



**Armand Balboni JD, PhD**  
Director, Medical & Legal Due  
Diligence Group



**Shawn Aspden CFA**  
Managing Director

## Investment Banking



**Michael Pollard MBA, CFA**  
Managing Director



**Claudia Hui PhD**  
Associate



**John Holyoake DPhil**  
Vice President



**Vincent Nadeau PhD**  
Associate



**James Rowland MSc**  
Vice President



**Chi Liu**  
Associate



**Evelyn Pau PhD**  
Associate

## OUR PEOPLE

### Equity Research



**David Martin PhD, MBA**  
Managing Director &  
Head of Equity Research



**Antonia Borovina PhD**  
Associate



**Prasath Pandurangan MBBS, CFA**  
Associate

### Corporate Staff



**Stephanie Mazzone CPA, CA**  
Chief Financial Officer



**Kari Tavener**  
Chief Compliance Officer



**Alycia Gambarotto**  
Accounting Analyst



**Eleanor Ndaiga**  
Communications Analyst



**Lili Salman**  
Office Manager

### Corporate & Business Development



**Andrew Duckman**  
Vice President, Corporate  
Development



**Matthew Johnson MSc**  
Vice President, Business  
Development

## NOTES

---



# LOGISTICS

## Keynote and Panel Discussion Sessions

Osgoode Ballroom

## Presentations

Hall A

Hall B

Hall C

## One-on-One Meetings


Hall E

## WiFi Access:


SHERATON\_MEETINGS

## Access Code:

BBHIC2018



 @bloomburton #BBHIC2018

 Bloom Burton & Co.

*B*loom Burton  
Award *G*ala



*T*hursday, September 27<sup>th</sup> 2018

*F*our Seasons Hotel

60 Yorkville Avenue  
Toronto, Ontario

*B*lack Tie



bloom burton & co

*/accelerating returns in healthcare*

BBHC

BLOOM BURTON & CO.  
HEALTHCARE INVESTOR  
CONFERENCE